Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Identifying putative substrates of Lon protease in Pseudomonas aeruginosa

ABSTRACT: We aim to identify potential substrates of the Lon protease in P. aeruginosa. Samples with the lon protease overexpressed or deleted were compared to the wild type to observe the proteins whose steady-state levels changed with change in Lon levels. We used spectinomycin to inhibit protein synthesis and observed the stability of proteins over 30 and 60 minutes to identify proteins whose stability also changed in response of Lon levels.

INSTRUMENT(S): Q Exactive HF

ORGANISM(S): Bacteria Pseudomonas Aeruginosa Pa1

SUBMITTER: Georgios Mermelekas

LAB HEAD: Kristina Jonas

PROVIDER: PXD063095 | Pride | 2025-06-13

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	20210618_GMKJAK_1_16__set1.raw	Raw
	20240527_GMKJAK34-52_set3.raw	Raw
	GMKJAK1-16_protein-results.xlsx	Xlsx
	GMKJAK34-52_set3_protein_results.xlsx	Xlsx
	checksum.txt	Txt

Items per page:

1 - 5 of 5

Similar Datasets

Identification of substrates of LarA-activated Lon protease and Identification of Lon protease interactome

Project description:With this analysis we aim to identify proteins that are substrates of LarA-activated Lon protease in Caulobacter crescentus. We will compare samples of wild type cells either harboring an empty vector (vector control, VC) or overexpressing 3xFLAG-tagged LarA (F-LarA). Based on our previous data we hypothesize that proteins affected by LarA-overexpression which results in Lon protease activation will decrease in levels compared to the vector control sample. The aim of this analysis is the identification of the interactome of the Lon protease in Caulobacter crescentus. It is a follow-up analysis of a project in which we were looking for novel substrates of the Lon protease in Caulobacter crescentus. To narrow down the list of potential substrates we obtained through the first analysis, we have purified the protease (Lon WT) as well an inactive TRAP mutant and interacting proteins using a Twin-Strep-tag (Iba lifesciences). As a control, a cell lysate without Strep-tag containing protein was included in the purification set-up. The aim is to identify the proteins that specifically interact with the Lon protease by mass spectrometry.

2023-10-25 | PXD036514 | Pride

The VE-cadherin/AmotL2 mechanosensory pathway suppresses aortic inflammation and the formation of abdominal aortic aneurysms

Project description:Arterial endothelial cells (ECs) have the ability to respond to mechanical forces exerted by laminar fluid shear stress. This response is of importance, as it is protective against vascular diseases such as atherosclerosis and aortic aneurysms. Mechanical forces are transmitted at the sites of adhesion to the basal membrane as well as cell-cell junctions where protein complexes connect to the cellular cytoskeleton to relay force into the cell. Here we present a novel protein complex that connects junctional VE-cadherin and radial actin filaments to the LINC complex in the nuclear membrane. We show that the scaffold protein AmotL2 is essential for the formation of radial actin filaments and the flow-induced alignment of aortic endothelial cells. The deletion of endothelial AmotL2 alters nuclear shape as well as subcellular positioning. Molecular analysis shows that VE-cadherin is mechanically associated with the nuclear membrane via binding to AmotL2 and Actin. Furthermore, the deletion of AmotL2 in ECs provoked a pro-inflammatory response and abdominal aortic aneurysms (AAA) in the aorta of mice on a normal diet. Remarkably, transcriptome analysis of AAA samples from human patients revealed a negative correlation between AmotL2 expression and inflammation of the aortic intima. These findings provide a conceptual framework regarding how mechanotransduction in the junctions is coupled with vascular diseases.

2024-10-17 | PXD039256 | Pride

U2OS LC MSMS upon siRNA-eIF4A3 or 5nM ActD treatment.

Project description:Proteome analysis in U2OS cells treated with siRNA against eIf4A3 or 5nM Actinomycin D.

2021-09-08 | PXD016005 | Pride

Remodeling of the human skeletal muscle proteome found after long-term endurance training but not after strength training

Project description:Proteomic characterization of skeletal muscle biopsies collected from the vastus lateralis of 44 male and female human subjects. Research subjects were divided in three different groups based on their individual exercise backgrounds and physical performance testing: 1) endurance trained (males; ME, n = 9 and females; FE, n = 9, with at least 15 years’ of regular training experience), 2) strength-trained males (MS, n = 9, with at least 15 years’ of regular training experience), and 3) age-matched healthy untrained controls (males, MC, n = 9 and females FC, n = 8, with a self-reported history of <2 exercise bouts per week over the past 15 years).

2024-01-26 | PXD044445 | Pride

The proteome of personalized tissue-engineered veins

Project description:Tissue-engineered veins were generated by reconditioning decellularized veins from both human and pig with whole-blood from respective species. Decellularized human vena femoralis from three donor were reconditioned with human whole blood from four donors. In addition, decellularized pig vena cava from three donors were reconditioned with pig whole blood from three different donors. The proteomes of the tissue-engineered veins were investigated applying the TMT-based proteomics to explore differences between species, regarding the gain of biological material by the reconditioning process.

2024-05-21 | PXD044069 | Pride

Functional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (subcellular localization and relocalization analysis)

Project description:The subcellular localization of proteins can be highly dynamic and regulated by post-translational modifications. Farnesylation is a lipid modification that enables anchoring of proteins to cellular membranes, and thus, spatially resolved signaling and activity. Due to the importance of farnesylation for cellular functions, farnesyltransferase inhibitors (FTIs) including tipifarnib were developed and are being tested in oncology clinical trials. The current lack of knowledge on the functional impact of FTIs on hundreds of farnesylation substrates limits response prediction and their use in cancer precision medicine. Here, we report a global functional proteomics investigation of farnesylation and the impact of tipifarnib in multiple lung cancer cell lines. This dataset includes global mapping of protein localization using our SubCellBarCode method, and analyses of tipifarnib-dependent protein relocalization.

2025-05-19 | PXD050490 | Pride

: Functional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (PTP4A1 silencing and IFN treatment of NCI-H1944 cells)

Project description:The subcellular localization of proteins can be highly dynamic and regulated by post-translational modifications. Farnesylation is a lipid modification that enables anchoring of proteins to cellular membranes, and thus, spatially resolved signaling and activity. Due to the importance of farnesylation for cellular functions, farnesyltransferase inhibitors (FTIs) including tipifarnib were developed and are being tested in oncology clinical trials. The current lack of knowledge on the functional impact of FTIs on hundreds of farnesylation substrates limits response prediction and their use in cancer precision medicine. Here, we report a global functional proteomics investigation of farnesylation in multiple lung cancer cell lines. In this dataset, we reveal farnesylated protein PTP4A1 as a regulator of interferon signaling using global proteomics data on PTP4A1-silenced and/or interferon gamma-stimulated NCI-H1944 cells.

2025-05-13 | PXD050446 | Pride

Molecular Profiling Defines Three Subtypes of Synovial Sarcoma

Project description:Synovial Sarcomas (SS) are characterized by the presence of the SS18::SSX fusion gene, which protein product induce chromatin changes through remodeling of the BAF complex (BRG1/BRM-associated factor complex), which leads to widespread alterations in gene expression that drive tumor development and progression. However, there are no comprehensive studies that integrate multi-omics approaches to fully understand the heterogeneity and molecular subtypes of SS. To elucidate the genomic events that drive phenotypic diversity in SS, we performed RNA and targeted DNA sequencing on 91 tumors from 55 patients. Our results were verified by proteomic analysis, public gene expression cohorts and single-cell RNA sequencing. Transcriptome profiling identified three distinct SS subtypes resembling the known histological subtypes: SS subtype I and was characterized by hyperproliferation, evasion of immune detection and a poor prognosis. SS subtype II and was dominated by a vascular-stromal component and had a significantly better outcome. SS Subtype III was characterized by biphasic differentiation, increased genomic complexity and immune suppression mediated by checkpoint inhibition, and poor prognosis despite good responses to neoadjuvant therapy. Chromosomal abnormalities were an independent significant risk factor for metastasis. KRT8 was identified as a key component for epithelial differentiation in biphasic tumors, potentially controlled by OVOL1 regulation. Our multi-omics analysis revealed biological and genetic variability between these subtypes, including key transcriptome patterns and secondary genomic events such as copy number alterations, could be associated with long-term outcomes. Our findings explain the histological grounds for SS classification and indicate that a significantly larger proportion of patients have high risk tumors (corresponding to SS subtype I) than previously believed.

2025-05-07 | PXD053789 | Pride

Functional proteomics-based investigation of the cellular response to farnesyl transferase inhibition in lung cancer (tipifarnib treatment of lung cancer cells)

Project description:The subcellular localization of proteins can be highly dynamic and regulated by post-translational modifications. Farnesylation is a lipid modification that enables anchoring of proteins to cellular membranes, and thus, spatially resolved signaling and activity. Due to the importance of farnesylation for cellular functions, farnesyltransferase inhibitors (FTIs) including tipifarnib were developed and are being tested in oncology clinical trials. The current lack of knowledge on the functional impact of FTIs on hundreds of farnesylation substrates limits response prediction and their use in cancer precision medicine. Here, we report a global functional proteomics investigation of the impact of tipifarnib in multiple lung cancer cell lines. This dataset includes proteome-wide analysis of the effects of tipifarnib at 6, 12, 24, 48 h timepoints. The data covers experiments in five lung cancer cell lines (NCI-H727, NCI-H1568, NCI-H1975, NCI-H2009 and NCI-H1944).

2025-05-13 | PXD050480 | Pride

Proteomic profiling in fibrolamellar carcinoma patient tumor tissue

Project description:Fibrolamellar carcinoma (FLC) is a rare, early-onset liver cancer. The five-year survival rate is low, and there is a critical need for new therapeutics. The primary driver in FLC is the fusion oncoprotein, DNAJ-PKAc, which remains challenging to target therapeutically. It is critical, therefore, to expand understanding of the FLC molecular landscape to identify druggable pathways/targets. To date, only one study has attempted to characterize the FLC proteome and metabolome, but with modest sample size (proteomics—n = 16 patient samples; metabolomics—n = 10 patient samples) and protein detection (n = 4620 proteins). We have performed the most comprehensive characterization of FLC in both proteomics (n = 23 patient samples; n = 8485 proteins) and metabolomics (n = 26 patient samples; n = 135 metabolites). Additionally, we have conducted respirometry analyses as well as RNAi- and small molecule inhibitor-mediated loss of function assays in FLC tumors and non-malignant liver tissue from patients. We propose a model of cellular energetics in FLC that centers on amino acids. Our model points to proline anabolism that is very likely mediated by ornithine aminotransferase hyperactivity and ornithine transcarbamylase hypoactivity with serine and glutamine catabolism providing the starting substrate. The metabolic rewiring in FLC proposed by our model, with a particular emphasis on mitochondria, can be exploited for therapeutic vulnerabilities.

2025-05-06 | PXD051527 | Pride